Core Scientific, Inc. Reports Q2 2026 Results: Strong Revenue Growth and Major Capital Raise
Key Highlights from the Q2 2026 Financial Report
- Substantial Cash Position: As of June 30, 2026, Core Scientific, Inc. (“the Company”) reported cash and cash equivalents of \$1.77 billion, a dramatic increase from \$37.3 million at March 31, 2026 and \$222 million at December 31, 2025. Including restricted cash, total liquidity reached \$2.55 billion, up from \$282.8 million at the start of the year. This remarkable increase is primarily due to a major capital raise, with debt issuance proceeds of \$4.28 billion during the first half of 2026.
- Revenue Growth: Q2 2026 digital asset self-mining revenue was \$21.5 million, while total digital asset self-mining revenue for the first half of 2026 reached \$129.6 million. Hosting revenue and other business lines contributed to total revenues, with consolidated revenues of \$279.4 million for the first half of the year.
- Gross Profit and Cost Structure: Gross profit for the quarter was \$70.0 million, with cost of revenue at \$214.2 million for the quarter and \$19.1 million for the previous quarter. The cost of digital asset self-mining for the quarter was \$33.7 million, resulting in a segment gross profit of \$21.5 million. However, the Company continued to experience high operating expenses, with selling, general and administrative expenses of \$49.4 million for the quarter.
- Net Loss Driven by Warrant Fair Value Change: The net loss for Q2 2026 was \$1.12 billion, primarily driven by a \$1.05 billion non-cash expense related to the change in fair value of outstanding warrants and contingent value rights, reflecting a significant appreciation in the Company’s stock price during the period. This non-cash charge is a direct result of the Company’s share price performance and does not reflect operating losses.
- Major Capital Raise: The Company completed a debt issuance of \$4.28 billion during the period, which dramatically increased its cash reserves and liquidity. This is a material event and signals both institutional confidence in the business and a significant war chest for future expansion or debt repayment.
- Significant Capital Expenditures: Core Scientific invested \$950.4 million in property, plant and equipment and \$232.5 million in land and development rights in the first half of 2026, underlining its aggressive expansion strategy.
- Balance Sheet Strength and Leverage: Total assets as of June 30, 2026, reached \$5.26 billion, with total liabilities of \$7.68 billion, resulting in a stockholders’ deficit of \$2.42 billion. The capital raise has significantly altered the Company’s balance sheet and leverage profile.
- Share Count: As of June 30, 2026, there were 319.6 million shares outstanding, up from 314.2 million at year-end 2025.
- Non-Cash Items and Shareholder Dilution: The large non-cash warrant fair value adjustment is directly tied to the Company’s share price increase and the structure of recent capital raises. Investors should be aware of potential future dilution as these warrants are exercised.
- Forward-Looking Statements: Management reiterated the Company’s growth ambitions and highlighted significant risks, including the ability to source electrical energy, finance and complete data center construction, and manage rapid expansion.
Shareholder Impact and Potential Price Sensitivity
- Massive Cash Influx via Debt Issuance: The successful capital raise of \$4.28 billion is a major, price-sensitive development. It gives the Company substantial financial flexibility for expansion, M&A, or balance sheet restructuring, but also increases leverage. The Company’s ability to deploy this capital profitably, manage its debt load, and deliver returns will be closely watched by investors and could materially affect the share price.
- Warrant Fair Value Impact: The large net loss is primarily non-cash and tied to the share price appreciation. While it does not represent operating weakness, it is a signal to investors of significant potential dilution if warrants are exercised at lower-than-market prices. This is both a risk (dilution) and an opportunity (validation of share price gains and capital raising ability).
- Expansion and CapEx: The Company’s commitment to large-scale capital expenditure demonstrates confidence in future growth, but brings execution and integration risks. The ability to convert these investments into profitable operations will be a key driver of valuation.
- Balance Sheet Leverage: The Company now has significant debt. Investors should monitor future interest expenses, refinancing risk, and any covenants tied to performance or asset coverage.
- Stock-Based Compensation: Stock-based compensation was \$36 million for the first half of 2026, a notable figure for existing shareholders evaluating dilution and management alignment.
- Forward-Looking Risks: Management highlights substantial risks, including market opportunity realization, operational execution, and external dependencies (e.g., power sourcing), all of which could significantly impact future performance and share value.
Financial Statements Overview (Q2 2026)
- Cash & Restricted Cash (June 30, 2026): \$2.55 billion
- Total Assets: \$5.26 billion
- Total Liabilities: \$7.68 billion
- Shareholders’ Deficit: (\$2.42) billion
- Q2 Net Loss: \$1.12 billion (primarily non-cash warrant fair value change)
- Digital Asset Self-Mining Revenue (Q2): \$21.5 million
- Digital Asset Self-Mining Revenue (YTD): \$129.6 million
- Gross Profit (Q2): \$70.0 million
- Selling, General & Administrative (Q2): \$49.4 million
- Weighted Average Shares Outstanding: 325.3 million (Q2 average)
Conclusion
Core Scientific’s Q2 2026 results signal a transformative quarter, with a massive capital raise driving liquidity and expansion opportunity, but also introducing new leverage and dilution risks. The non-cash loss from warrant revaluation reflects the Company’s share price gains but highlights potential shareholder dilution going forward. Investors should focus on how the Company deploys this new capital, manages debt, and executes on its aggressive expansion to drive future value. These developments are material and could significantly affect the share price, both positively (due to growth and confidence) and negatively (if execution or dilution risks materialize).
Disclaimer
This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties. Investors should review the Company’s full filings and consult with their financial advisors before making investment decisions.
